Sacubitril-Valsartan

Phase 3Small molecule

FFundación Pública Andaluza para la gestión de la Investigación en Sevilla

Sacubitril-Valsartan is one of 173 small molecule programs targeting Takotsubo cardiomyopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

172

Competitors

Pipeline

Status by Indication[3][1]

Indication

Takotsubo CardiomyopathyActive, not recruiting

Cardiac FailureRecruiting

Myocardial InfarctionNot yet recruiting

Heart FailureCompleted

CardiotoxicityRecruiting

ALSActive, not recruiting

HemodialysisRecruiting

Safety and EfficacyRecruiting

Dialysis PatientsNot yet recruiting

Takotsubo CardiomyopathyPreclinical

Active, not recruiting

Cardiac FailurePhase 1

Recruiting

Myocardial InfarctionPhase 3

Not yet recruiting

Heart FailurePhase 3

Completed

CardiotoxicityPhase 3

Recruiting

ALSPhase 3

Active, not recruiting

HemodialysisPhase 2

Recruiting

Safety and EfficacyPhase 3

Recruiting

Dialysis PatientsPhase 3

Not yet recruiting

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Sacubitril-Valsartan

FFundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 3

14 2

Bayer Aspirin

Bayer

Preclinical

2 3

Amidate

Pfizer

Preclinical

1 4

Activase

Xifaxan

2 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Potassium Iodide

MMeda Pharmaceuticals

Preclinical

1 8

GLP-1

RRigshospitalet, Denmark

Preclinical

2 9

Optimal Medical Therapy

HHelios Health Institute GmbH

Preclinical

2 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Recruiting

Study completion

NCT04971720

Q2 2027

Phase 3Not yet recruiting

Heart Failure

NCT06712030

Q3 2028

PreclinicalRecruiting

Takotsubo Cardiomyopathy

NCT07491718

Q4 2028

PreclinicalRecruiting

Heart Failure

NCT05194111

Phase 3Recruiting

Heart Failure

NCT05508035

ApprovedRecruiting

Coronary Artery Disease

NCT07572032

Clinical

Trials by Indication[1]

Heart Failure14 trials

Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study

Completed·—·N/A·NCT04587947·63 enrolled

Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure

Unknown status·UUniversity of Leipzig··NCT04498780·117 enrolled

Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

Not yet recruiting·PPuerta de Hierro University Hospital·Phase 3·NCT06712030·114 enrolled

Show 11 more trials

Sacubitril/Valsartan Versus Valsartan in Heart Failure With Improved Ejection Fraction

Unknown status·SSamsung Medical Center··NCT04803175·100 enrolled

Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction

Unknown status·—·Phase 4·NCT05487261·260 enrolled

Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation

Active, not recruiting·ZZiekenhuis Oost-Limburg·Phase 4·NCT05991284·84 enrolled

The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure

Completed·AAmir Safwat·Phase 4·NCT04688294·60 enrolled

Sacubitril-valsartan in Patients With Heart Failure.

Recruiting·—·N/A·NCT07341893·60 enrolled

Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction

Withdrawn·FFlinders University·Phase 3·NCT04128891

Changes in the T-wave Alternans in Patients With Heart Failure Treated Wih Sacubitril-Valsartan

Unknown status·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla··NCT04185103·20 enrolled

Effects of Sacubitril/Valsartan on Exercise Capacity, Natriuretic Peptides and Ventricular Remodeling in Heart Failure

Completed·CCentro Cardiologico Monzino··NCT04434170·112 enrolled

Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy

Completed·—·Phase 4·NCT04575675·78 enrolled

The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction

Recruiting·JJohn Paul II Hospital, Krakow·Phase 3·NCT05508035·488 enrolled

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF)

Recruiting·VVirginia Commonwealth University·Preclinical·NCT05194111·70 enrolled

Cardiotoxicity1 trial

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Recruiting·SSilesian Centre for Heart Diseases·Phase 4·NCT05465031·600 enrolled

Hypertension1 trial

Sacubitril/Valsartan in Resistant Hypertension

Completed·HHospital Geral Roberto Santos·Phase 2·NCT04637152·80 enrolled

Cardiac1 trial

Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output

Withdrawn·TThe Cleveland Clinic·Phase 4·NCT04206865

Cardiac Failure1 trial

Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial

Recruiting·KKhawaja Danish Ali·Phase 1·NCT07444398·130 enrolled

16 more indications

Safety and Efficacy1 trial

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

Recruiting·TThe Cleveland Clinic·Phase 4·NCT04191681·50 enrolled

Hemodialysis1 trial

Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation

Recruiting·—·Phase 2·NCT05498181·100 enrolled

ALS1 trial

Sacubitril/Valsartan in Left Ventricular Assist Device Recipients

Active, not recruiting·UUniversity of Zagreb·Phase 4·NCT04103554·60 enrolled

Atrial Fibrillation1 trial

Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT05528419·320 enrolled

Prospective1 trial

Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation

Unknown status·MMark Ledwidge·Phase 2·NCT04687111·250 enrolled

Not yet recruiting·WWest China Hospital·Phase 3·NCT04912167·376 enrolled

TIA1 trial

Initiation of ARNi and SGLT2i in Patients With HFrEF

Completed·UUniversidade do Porto·Phase 4·NCT05989503·62 enrolled

Chronic1 trial

Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB

Unknown status·SSamsung Medical Center·Phase 2·NCT05212597·100 enrolled

Dialysis Patients1 trial

The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF

Not yet recruiting·—·Phase 4·NCT07417215·60 enrolled

Takotsubo cardiomyopathy1 trial

Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy

Recruiting·UUniversity of Edinburgh·Preclinical·NCT07491718·100 enrolled

Coronary Artery Disease1 trial

DELayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected aetiologY (DELAY-HF), Pilot Study

Recruiting·KKyungsub Song·Approved·NCT07572032·80 enrolled

Heart Failure With Preserved Ejection Fraction1 trial

Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction

Withdrawn·BBrigham and Women's Hospital·Approved·NCT06536309

Acute Decompensated Heart Failure (ADHF)1 trial

Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure - CAESAR (a Randomized Controlled Trial)

Completed·NNational Heart Institute, Egypt·Preclinical·NCT07023016·515 enrolled

Unspecified1 trial

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

Recruiting·UUniversity of Alabama at Birmingham·Phase 2/3·NCT04971720·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for Sacubitril-Valsartan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sacubitril-Valsartan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sacubitril-Valsartan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fundación Pública Andaluza para la gestión de la Investigación en Sevilla company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFundación Pública Andaluza para la gestión de la Investigación en Sevilla

Sacubitril-Valsartan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q3 2028

Q4 2028

Trials by Indication[1]

Heart Failure14 trials

Cardiotoxicity1 trial

Hypertension1 trial

Cardiac1 trial

Cardiac Failure1 trial

Safety and Efficacy1 trial

Hemodialysis1 trial

ALS1 trial

Atrial Fibrillation1 trial

Prospective1 trial

Observational Study1 trial

Catheter Ablation1 trial

Myocardial Infarction1 trial

TIA1 trial

Chronic1 trial

Dialysis Patients1 trial

Takotsubo cardiomyopathy1 trial

Coronary Artery Disease1 trial

Heart Failure With Preserved Ejection Fraction1 trial

Acute Decompensated Heart Failure (ADHF)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News